Are you interested in learning about or participating in a hepatitis C virus (HCV) clinical research study? If so, choosing to participate in a clinical trial is an important personal decision.

To learn what a clinical trial is, the pros and cons of participating, who is eligible to participate, and many more commonly asked questions CLICK HERE


This will provide you with detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials. To find a clinical trial in your area CLICK HERE 
 

Here are some people to contact about the many clinical trials going on right now in the state of Colorado:


Sherry Rogers, CRC
Clinical Research Department
South Denver Gastroenterology
303-406-4139
 
Michael Cookson
Hepatology Research Lead Coordinator
University of Colorado Denver
(303) 724-1876

 
Here are several websites to access for information on clinical trials outside of Colorado:
www.clinicaltrials.gov
www.centerwatch.com
www.ifpma.org/clinicaltrials
 
To learn about hepatitis C treatment currently in the pipeline, click here http://www.hcvdrugs.com/
 
Quick Reference guide to better understand the various “Phases” of clinical trials:
 
PHASE I TRIALS: Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

PHASE II TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.

PHASE III TRIALS: Expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.